Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

Zaira Raquel Palacios-Baena; Belén Gutiérrez-Gutiérrez; Esther Calbo; Benito Almirante; Pierluigi Viale; Antonio Oliver; Vicente Pintado; Oriol Gasch; Luis Martínez-Martínez; Johann Pitout; Murat Akova; Carmen Peña; José Molina Gil-Bermejo; Alicia Hernández; Mario Venditti; Nuria Prim; German Bou; Evelina Tacconelli; Mario Tumbarello; Axel Hamprecht; Helen Giamarellou; Manel Almela; Federico Pérez; Mitchell J. Schwaber; Joaquín Bermejo; Warren Lowman; Po Ren Hsueh; José Ramón Paño-Pardo; Julián Torre-Cisneros; Maria Souli; Robert A. Bonomo; Yehuda Carmeli; David L. Paterson; Álvaro Pascual; Jesús Rodríguez-Baño; J. Gálvez; M. Falcone; A. Russo; G. Daikos; E. M. Trecarichi; A. R. Losito; J. Gómez; E. Iosifidis; E. Roilides; I. Karaiskos; Y. Doi; F. F. Tuon; F. Navarro; B. Mirelis; J. A. Martínez; C. De La Calle; L. Morata; R. San Juan; M. Fernández-Ruiz; N. Larrosa; M. Puig; J. Molina; V. González; V. Rucci; E. Ruiz De Gopegui; C. I. Marinescu; M. C. Fariñas; M. E. Cano; M. Gozalo; M. Mora-Rillo; S. Gómez-Zorrilla; F. Tubau; S. Pournaras; A. Tsakris; O. Zarkotou; K. Azap; A. Antoniadou; G. Poulakou; D. Virmani; Cano; I. Machuca; Helvaci; A. O. Sahin; P. Ruiz-Garbajosa; M. Bartoletti; M. Giannella; S. Peter; C. Badia; M. Xercavins; D. Fontanals; E. Jové

doi:10.1093/cid/cix606

Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

Zaira Raquel Palacios-Baena, Belén Gutiérrez-Gutiérrez, Esther Calbo, Benito Almirante, Pierluigi Viale, Antonio Oliver, Vicente Pintado, Oriol Gasch, Luis Martínez-Martínez, Johann Pitout, Murat Akova, Carmen Peña, José Molina Gil-Bermejo, Alicia Hernández, Mario Venditti, Nuria Prim, German Bou, Evelina Tacconelli, Mario Tumbarello, Axel HamprechtHelen Giamarellou, Manel Almela, Federico Pérez, Mitchell J. Schwaber, Joaquín Bermejo, Warren Lowman, Po Ren Hsueh, José Ramón Paño-Pardo, Julián Torre-Cisneros, Maria Souli, Robert A. Bonomo, Yehuda Carmeli, David L. Paterson, Álvaro Pascual, Jesús Rodríguez-Baño, J. Gálvez, M. Falcone, A. Russo, G. Daikos, E. M. Trecarichi, A. R. Losito, J. Gómez, E. Iosifidis, E. Roilides, I. Karaiskos, Y. Doi, F. F. Tuon, F. Navarro, B. Mirelis, J. A. Martínez, C. De La Calle, L. Morata, R. San Juan, M. Fernández-Ruiz, N. Larrosa, M. Puig, J. Molina, V. González, V. Rucci, E. Ruiz De Gopegui, C. I. Marinescu, M. C. Fariñas, M. E. Cano, M. Gozalo, M. Mora-Rillo, S. Gómez-Zorrilla, F. Tubau, S. Pournaras, A. Tsakris, O. Zarkotou, K. Azap, A. Antoniadou, G. Poulakou, D. Virmani, Cano, I. Machuca, Helvaci, A. O. Sahin, P. Ruiz-Garbajosa, M. Bartoletti, M. Giannella, S. Peter, C. Badia, M. Xercavins, D. Fontanals, E. Jové

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Abstract

Background. There is little information about the efficacy of active alternative drugs to carbapenems except ?-lactam/?-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum ?-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems. Methods. A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed. Results. Overall, 335 patients were included; 249 received empiric carbapenems and 86 OADs. The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients). Empiric therapy with OADs was not associated with mortality (hazard ratio [HR], 0.75; 95% confidence interval [CI], .38-1.48) in the Cox regression analysis. Propensity score-matched pairs, subgroups, and sensitivity analyses did not show different trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16). OADs were neither associated with 14-day clinical failure (adjusted odds ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay. Conclusions. We were unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems. This information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E.

Original language	English
Pages (from-to)	1615-1623
Number of pages	9
Journal	Clinical Infectious Diseases
Volume	65
Issue number	10
DOIs	https://doi.org/10.1093/cid/cix606
Publication status	Published - 15-11-2017
Externally published	Yes

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/cix606

Cite this

Palacios-Baena, Z. R., Gutiérrez-Gutiérrez, B., Calbo, E., Almirante, B., Viale, P., Oliver, A., Pintado, V., Gasch, O., Martínez-Martínez, L., Pitout, J., Akova, M., Peña, C., Molina Gil-Bermejo, J., Hernández, A., Venditti, M., Prim, N., Bou, G., Tacconelli, E., Tumbarello, M., ... Jové, E. (2017). Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort. Clinical Infectious Diseases, 65(10), 1615-1623. https://doi.org/10.1093/cid/cix606

@article{193971a682ba47498ce756897929bdb4,

title = "Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort",

abstract = "Background. There is little information about the efficacy of active alternative drugs to carbapenems except ?-lactam/?-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum ?-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems. Methods. A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed. Results. Overall, 335 patients were included; 249 received empiric carbapenems and 86 OADs. The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients). Empiric therapy with OADs was not associated with mortality (hazard ratio [HR], 0.75; 95% confidence interval [CI], .38-1.48) in the Cox regression analysis. Propensity score-matched pairs, subgroups, and sensitivity analyses did not show different trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16). OADs were neither associated with 14-day clinical failure (adjusted odds ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay. Conclusions. We were unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems. This information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E.",

keywords = "aminoglycosides, antimicrobial resistance, bloodstream infections, extended-spectrum ?-lactamase-producing Enterobacteriaceae, therapy",

author = "Palacios-Baena, {Zaira Raquel} and Bel{\'e}n Guti{\'e}rrez-Guti{\'e}rrez and Esther Calbo and Benito Almirante and Pierluigi Viale and Antonio Oliver and Vicente Pintado and Oriol Gasch and Luis Mart{\'i}nez-Mart{\'i}nez and Johann Pitout and Murat Akova and Carmen Pe{\~n}a and {Molina Gil-Bermejo}, Jos{\'e} and Alicia Hern{\'a}ndez and Mario Venditti and Nuria Prim and German Bou and Evelina Tacconelli and Mario Tumbarello and Axel Hamprecht and Helen Giamarellou and Manel Almela and Federico P{\'e}rez and Schwaber, {Mitchell J.} and Joaqu{\'i}n Bermejo and Warren Lowman and Hsueh, {Po Ren} and Pa{\~n}o-Pardo, {Jos{\'e} Ram{\'o}n} and Juli{\'a}n Torre-Cisneros and Maria Souli and Bonomo, {Robert A.} and Yehuda Carmeli and Paterson, {David L.} and {\'A}lvaro Pascual and Jes{\'u}s Rodr{\'i}guez-Ba{\~n}o and J. G{\'a}lvez and M. Falcone and A. Russo and G. Daikos and Trecarichi, {E. M.} and Losito, {A. R.} and J. G{\'o}mez and E. Iosifidis and E. Roilides and I. Karaiskos and Y. Doi and Tuon, {F. F.} and F. Navarro and B. Mirelis and Mart{\'i}nez, {J. A.} and {De La Calle}, C. and L. Morata and {San Juan}, R. and M. Fern{\'a}ndez-Ruiz and N. Larrosa and M. Puig and J. Molina and V. Gonz{\'a}lez and V. Rucci and {Ruiz De Gopegui}, E. and Marinescu, {C. I.} and Fari{\~n}as, {M. C.} and Cano, {M. E.} and M. Gozalo and M. Mora-Rillo and S. G{\'o}mez-Zorrilla and F. Tubau and S. Pournaras and A. Tsakris and O. Zarkotou and K. Azap and A. Antoniadou and G. Poulakou and D. Virmani and Cano and I. Machuca and Helvaci and Sahin, {A. O.} and P. Ruiz-Garbajosa and M. Bartoletti and M. Giannella and S. Peter and C. Badia and M. Xercavins and D. Fontanals and E. Jov{\'e}",

note = "Publisher Copyright: {\textcopyright} The Author 2017.",

year = "2017",

month = nov,

day = "15",

doi = "10.1093/cid/cix606",

language = "English",

volume = "65",

pages = "1615--1623",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "10",

}

Palacios-Baena, ZR, Gutiérrez-Gutiérrez, B, Calbo, E, Almirante, B, Viale, P, Oliver, A, Pintado, V, Gasch, O, Martínez-Martínez, L, Pitout, J, Akova, M, Peña, C, Molina Gil-Bermejo, J, Hernández, A, Venditti, M, Prim, N, Bou, G, Tacconelli, E, Tumbarello, M, Hamprecht, A, Giamarellou, H, Almela, M, Pérez, F, Schwaber, MJ, Bermejo, J, Lowman, W, Hsueh, PR, Paño-Pardo, JR, Torre-Cisneros, J, Souli, M, Bonomo, RA, Carmeli, Y, Paterson, DL, Pascual, Á, Rodríguez-Baño, J, Gálvez, J, Falcone, M, Russo, A, Daikos, G, Trecarichi, EM, Losito, AR, Gómez, J, Iosifidis, E, Roilides, E, Karaiskos, I, Doi, Y, Tuon, FF, Navarro, F, Mirelis, B, Martínez, JA, De La Calle, C, Morata, L, San Juan, R, Fernández-Ruiz, M, Larrosa, N, Puig, M, Molina, J, González, V, Rucci, V, Ruiz De Gopegui, E, Marinescu, CI, Fariñas, MC, Cano, ME, Gozalo, M, Mora-Rillo, M, Gómez-Zorrilla, S, Tubau, F, Pournaras, S, Tsakris, A, Zarkotou, O, Azap, K, Antoniadou, A, Poulakou, G, Virmani, D, Cano, Machuca, I, Helvaci, Sahin, AO, Ruiz-Garbajosa, P, Bartoletti, M, Giannella, M, Peter, S, Badia, C, Xercavins, M, Fontanals, D & Jové, E 2017, 'Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort', Clinical Infectious Diseases, vol. 65, no. 10, pp. 1615-1623. https://doi.org/10.1093/cid/cix606

Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort. / Palacios-Baena, Zaira Raquel; Gutiérrez-Gutiérrez, Belén; Calbo, Esther et al.
In: Clinical Infectious Diseases, Vol. 65, No. 10, 15.11.2017, p. 1615-1623.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae

T2 - Results from the INCREMENT Cohort

AU - Palacios-Baena, Zaira Raquel

AU - Gutiérrez-Gutiérrez, Belén

AU - Calbo, Esther

AU - Almirante, Benito

AU - Viale, Pierluigi

AU - Oliver, Antonio

AU - Pintado, Vicente

AU - Gasch, Oriol

AU - Martínez-Martínez, Luis

AU - Pitout, Johann

AU - Akova, Murat

AU - Peña, Carmen

AU - Molina Gil-Bermejo, José

AU - Hernández, Alicia

AU - Venditti, Mario

AU - Prim, Nuria

AU - Bou, German

AU - Tacconelli, Evelina

AU - Tumbarello, Mario

AU - Hamprecht, Axel

AU - Giamarellou, Helen

AU - Almela, Manel

AU - Pérez, Federico

AU - Schwaber, Mitchell J.

AU - Bermejo, Joaquín

AU - Lowman, Warren

AU - Hsueh, Po Ren

AU - Paño-Pardo, José Ramón

AU - Torre-Cisneros, Julián

AU - Souli, Maria

AU - Bonomo, Robert A.

AU - Carmeli, Yehuda

AU - Paterson, David L.

AU - Pascual, Álvaro

AU - Rodríguez-Baño, Jesús

AU - Gálvez, J.

AU - Falcone, M.

AU - Russo, A.

AU - Daikos, G.

AU - Trecarichi, E. M.

AU - Losito, A. R.

AU - Gómez, J.

AU - Iosifidis, E.

AU - Roilides, E.

AU - Karaiskos, I.

AU - Doi, Y.

AU - Tuon, F. F.

AU - Navarro, F.

AU - Mirelis, B.

AU - Martínez, J. A.

AU - De La Calle, C.

AU - Morata, L.

AU - San Juan, R.

AU - Fernández-Ruiz, M.

AU - Larrosa, N.

AU - Puig, M.

AU - Molina, J.

AU - González, V.

AU - Rucci, V.

AU - Ruiz De Gopegui, E.

AU - Marinescu, C. I.

AU - Fariñas, M. C.

AU - Cano, M. E.

AU - Gozalo, M.

AU - Mora-Rillo, M.

AU - Gómez-Zorrilla, S.

AU - Tubau, F.

AU - Pournaras, S.

AU - Tsakris, A.

AU - Zarkotou, O.

AU - Azap, K.

AU - Antoniadou, A.

AU - Poulakou, G.

AU - Virmani, D.

AU - Cano,

AU - Machuca, I.

AU - Helvaci,

AU - Sahin, A. O.

AU - Ruiz-Garbajosa, P.

AU - Bartoletti, M.

AU - Giannella, M.

AU - Peter, S.

AU - Badia, C.

AU - Xercavins, M.

AU - Fontanals, D.

AU - Jové, E.

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Background. There is little information about the efficacy of active alternative drugs to carbapenems except ?-lactam/?-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum ?-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems. Methods. A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed. Results. Overall, 335 patients were included; 249 received empiric carbapenems and 86 OADs. The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients). Empiric therapy with OADs was not associated with mortality (hazard ratio [HR], 0.75; 95% confidence interval [CI], .38-1.48) in the Cox regression analysis. Propensity score-matched pairs, subgroups, and sensitivity analyses did not show different trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16). OADs were neither associated with 14-day clinical failure (adjusted odds ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay. Conclusions. We were unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems. This information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E.

AB - Background. There is little information about the efficacy of active alternative drugs to carbapenems except ?-lactam/?-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum ?-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems. Methods. A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed. Results. Overall, 335 patients were included; 249 received empiric carbapenems and 86 OADs. The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients). Empiric therapy with OADs was not associated with mortality (hazard ratio [HR], 0.75; 95% confidence interval [CI], .38-1.48) in the Cox regression analysis. Propensity score-matched pairs, subgroups, and sensitivity analyses did not show different trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16). OADs were neither associated with 14-day clinical failure (adjusted odds ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay. Conclusions. We were unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems. This information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E.

KW - aminoglycosides

KW - antimicrobial resistance

KW - bloodstream infections

KW - extended-spectrum ?-lactamase-producing Enterobacteriaceae

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85032746020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032746020&partnerID=8YFLogxK

U2 - 10.1093/cid/cix606

DO - 10.1093/cid/cix606

M3 - Article

C2 - 29020250

AN - SCOPUS:85032746020

SN - 1058-4838

VL - 65

SP - 1615

EP - 1623

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 10

ER -

Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this